Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline

OBJECTIVES: Preclinical Alzheimers disease (AD) patients may or may not show cognitive impairment on testing. AD biomarkers are central to the identification of those at low, intermediate, or high risk of later dementia due to AD. We investigated biomarker distribution in those identified as subject...

Descripción completa

Detalles Bibliográficos
Autores principales: Eliassen, Carl F., Reinvang, Ivar, Selnes, Per, Grambaite, Ramune, Fladby, Tormod, Hessen, Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607543/
https://www.ncbi.nlm.nih.gov/pubmed/28948074
http://dx.doi.org/10.1002/brb3.776

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607543/
https://www.ncbi.nlm.nih.gov/pubmed/28948074
http://dx.doi.org/10.1002/brb3.776

Ejemplares similares